These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28977680)

  • 21. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
    Chen Y; Huang Y; Reiberger T; Duyverman AM; Huang P; Samuel R; Hiddingh L; Roberge S; Koppel C; Lauwers GY; Zhu AX; Jain RK; Duda DG
    Hepatology; 2014 Apr; 59(4):1435-47. PubMed ID: 24242874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
    Fendrich V; Maschuw K; Rehm J; Buchholz M; Holler JP; Slater EP; Bartsch DK; Waldmann J
    ScientificWorldJournal; 2012; 2012():529151. PubMed ID: 23346016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
    Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sorafenib on murine liver regeneration.
    Hora C; Romanque P; Dufour JF
    Hepatology; 2011 Feb; 53(2):577-86. PubMed ID: 21274878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
    Qiu YQ; Zhou J; Kang XS; Shen-Tu JZ; Ding LM; Tan FL; Guo J; Li LJ
    Afr J Tradit Complement Altern Med; 2012; 9(3):431-9. PubMed ID: 23983378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor.
    El-Ashmawy NE; Khedr EG; El-Bahrawy HA; Abd El-Fattah EE
    Clin Exp Med; 2017 May; 17(2):185-191. PubMed ID: 27085325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9.
    Nakamura K; Hatano E; Narita M; Miyagawa-Hayashino A; Koyama Y; Nagata H; Iwaisako K; Taura K; Uemoto S
    J Hepatol; 2012 Nov; 57(5):1037-43. PubMed ID: 22796153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib inhibits liver regeneration in rats.
    Andersen KJ; Knudsen AR; Kannerup AS; Sasanuma H; Nyengaard JR; Hamilton-Dutoit S; Ladekarl M; Mortensen FV
    HPB (Oxford); 2013 Dec; 15(12):944-50. PubMed ID: 23461776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
    Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
    Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
    Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit.
    Wang M; Xu S; Wu C; Liu X; Tao H; Huang Y; Liu Y; Zheng P; Zhu W
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5450-5454. PubMed ID: 27777009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
    Shu M; Zai X; Zhang B; Wang R; Lin Z
    PLoS One; 2016; 11(1):e0147048. PubMed ID: 26784451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
    Jia L; Ma X; Gui B; Ge H; Wang L; Ou Y; Tian L; Chen Z; Duan Z; Han J; Fu R
    PLoS One; 2015; 10(2):e0117757. PubMed ID: 25679376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib.
    Ross FA; Hawley SA; Auciello FR; Gowans GJ; Atrih A; Lamont DJ; Hardie DG
    Cell Chem Biol; 2017 Jul; 24(7):813-824.e4. PubMed ID: 28625738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
    Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.